DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages
[Data availability]
Mouse scRNA-seq and TCR-seq data have been deposited in Gene Expression Omnibus (GEO) under accession number GSE296798. Human scRNA-seq data have been deposited as raw count files in GEO under accession number GSE296805. Human scRNA-seq raw fastq files have not been made publicly available due to privacy concerns but can be made available from the corresponding authors upon request. All requests will be fulfilled within 2 weeks, with data being made available permanently to the requester. Publicly available transcriptional data from the METABRIC dataset39,70 were downloaded from cBioPortal (https://www.cbioportal.org/study/summary?id=brca_metabric) on 18 November 2020. The remaining data supporting the findings of this study are available within the article, Supplementary Information or Source Data files and/or from the corresponding authors upon request. Source data are provided with this paper., Resistance to cyclin-dependent kinase 4/6 (CDK4/CDK6) inhibitors leads to treatment failure and disease progression in women with hormone receptor+HER2− (HR+HER2−) breast cancer (BC). We delineated a hypoxia-sensitive, CCL2-dependent pathway recruiting interleukin-17A (IL-17A)-secreting γδ T cells to mouse HR+HER2− BCs following CDK4/CDK6 inhibition, resulting in repolarization of tumor-associated macrophages (TAMs) toward an immunosuppressive CX3CR1+ phenotype associated with resistance. Increased IL-17A signaling and intratumoral γδ T cell abundance positively correlated with advanced grade and/or reduced survival in two cohorts of individuals with HR+HER2− BC. Circulating γδ T cells and plasma CCL2 levels negatively correlated with progression in an independent series of individuals with HR+HER2− BC receiving CDK4/CDK6 inhibitors. Intratumoral γδ T cells were increased in post- versus pretreatment biopsies from individuals with HR+HER2− BC relapsing on CDK4/CDK6 inhibitors. CX3CR1+ TAMs had negative prognostic impact in women with HR+HER2− BC receiving neoadjuvant PD-1 blockage and radiotherapy. Thus, γδ T cells and CX3XR1+ TAMs may favor resistance to CDK4/CDK6 inhibitors in individuals with HR+HER2− BC., We are indebted to S. Chen (Weill Cornell Medical College) for the kind gift of an ELISA kit for human CCL2 quantification and to A. Y. Ho (Duke University Medical Center) for coleading with S.L.S. the clinical study NCT03366844 and providing constructive input on the paper. G.P. and L.G. are grateful to the William Guy Forbeck Research Foundation (Carbondale, CO) for fostering the dissemination of knowledge, promoting scientific collaboration and supporting the training of the next generation of leaders in cancer research. This work has been partially sponsored by the 2019 Laura Ziskin Prize in Translational Research (ZP-6177, S.C.F. and H.L.M.) from Stand Up to Cancer and by a Breakthrough Level 2 grant from the US Department of Defense (DoD) Breast Cancer Research Program (BCRP; BC210945, L.G. and S.R.V.K.). The clinical study NCT03366844 was sponsored by the Breast Cancer Research Foundation. C.G. is supported by the American Italian Cancer Foundation (223565-01). F.F. was supported by the Austrian Science Fund (T 974-B30) and by the Oesterreichische Nationalbank (18496). The laboratory of M.E.R.-R. is supported by the Fundación CRIS, Programa Talento Clínico 2020 (PR_TCL_2020-03), the Cancer Research UK (C18915/A29362), FCAECC and AIRC under the Accelerator Award Programme, the RTC2019-006860-1 supported by MCIN/AEI/10.13039/501100011033 and the Instituto de Salud Carlos III through project PI20/00434. B.S. is supported by a grant from the Deutsche Krebshilfe, Integrate project. L.d.l.C.-M. is supported by a grant from the Andalusian Public Foundation Progress and Health (PI-0502-2014 FPS-2014). E.G.-M. is supported by ‘Calasparra se Mueve’, a research funding initiative inspired by women from Calasparra (Murcia), Spain. L.G. is/has also been supported (as a principal investigator unless otherwise indicated) by one R01 grant from the NIH/NCI (CA271915), one Breakthrough Level 2 grant from the US DoD BCRP (BC180476P1), a grant from the STARR Cancer Consortium (I16-0064), a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (W81XWH2120034, S.C.F.), a U54 grant from NIH/NCI (CA274291, principal investigators: J. Deasy, S.C.F., R. Weichselbaum), the 2019 Laura Ziskin Prize in Translational Research (ZP-6177, S.C.F.) from Stand Up to Cancer, a Mantle Cell Lymphoma Research Initiative (MCL-RI, principal investigator: S. Chen-Kiang) grant from the Leukemia and Lymphoma Society, a Rapid Response Grant from the Functional Genomics Initiative, startup funds from the Department of Radiation Oncology at Weill Cornell Medicine, industrial collaborations with Lytix Biopharma, Promontory and Onxeo and by donations from Promontory, the Luke Heller TECPR2 Foundation, Sotio, Lytix Biopharma, Onxeo, Ricerchiamo and Noxopharm. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the paper., Peer reviewed
Project:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTC2019-006860-1
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20-00434
DOI: http://hdl.handle.net/10261/412168, https://api.elsevier.com/content/abstract/scopus_id/105009914085
HANDLE: http://hdl.handle.net/10261/412168, https://api.elsevier.com/content/abstract/scopus_id/105009914085